09:32 AM EDT, 10/16/2025 (MT Newswires) -- Whitehawk Therapeutics ( WHWK ) shares were sharply higher Thursday after the company formed a multi-year collaboration with Tempus AI ( TEM ) to leverage Tempus' real-world dataset to advance biomarker-driven research and further Whitehawk Therapeutics' ( WHWK ) oncology pipeline, Tempus said.

The collaboration will focus on Whitehawk Therapeutics' ( WHWK ) antibody drug conjugates portfolio, which includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers, the company said.

Shares of Tempus AI ( TEM ) and Whitehawk were up 5.3% and 54.7%, respectively, in early trading.

Price: 3.28, Change: +1.17, Percent Change: +55.45